Bremer Bank National Association boosted its position in Eli Lilly And Co (NYSE:LLY) by 0.7% in the third quarter, HoldingsChannel.com reports. The firm owned 18,069 shares of the company’s stock after purchasing an additional 121 shares during the quarter. Bremer Bank National Association’s holdings in Eli Lilly And Co were worth $2,674,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Coastal Capital Group Inc. lifted its position in Eli Lilly And Co by 153.8% in the second quarter. Coastal Capital Group Inc. now owns 165 shares of the company’s stock worth $27,000 after purchasing an additional 100 shares during the period. Hoover Financial Advisors Inc. acquired a new stake in Eli Lilly And Co in the second quarter worth approximately $33,000. Ayalon Holdings Ltd. acquired a new stake in Eli Lilly And Co in the second quarter worth approximately $55,000. Truvestments Capital LLC lifted its position in Eli Lilly And Co by 79.9% in the second quarter. Truvestments Capital LLC now owns 358 shares of the company’s stock worth $58,000 after purchasing an additional 159 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Eli Lilly And Co by 49.4% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 363 shares of the company’s stock valued at $60,000 after buying an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.
NYSE LLY traded up $0.73 on Friday, hitting $142.38. The company’s stock had a trading volume of 2,427,462 shares, compared to its average volume of 3,860,209. The company has a quick ratio of 0.94, a current ratio of 1.22 and a debt-to-equity ratio of 3.53. Eli Lilly And Co has a 1-year low of $106.25 and a 1-year high of $170.75. The company’s 50-day moving average is $149.07 and its 200 day moving average is $153.60. The firm has a market cap of $136.18 billion, a PE ratio of 23.11, a PEG ratio of 1.25 and a beta of 0.19.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.08%. The ex-dividend date of this dividend is Thursday, November 12th. Eli Lilly And Co’s dividend payout ratio is currently 49.01%.
In other news, SVP Melissa S. Barnes sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $151.01, for a total value of $755,050.00. Following the sale, the senior vice president now directly owns 23,580 shares of the company’s stock, valued at approximately $3,560,815.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.09% of the company’s stock.
Several research firms have issued reports on LLY. Berenberg Bank began coverage on Eli Lilly And Co in a report on Tuesday, September 29th. They issued a “hold” rating and a $144.00 price target on the stock. Morgan Stanley raised Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $149.55 to $176.00 in a report on Thursday, September 3rd. They noted that the move was a valuation call. Mizuho upped their price target on Eli Lilly And Co from $155.00 to $164.00 and gave the company a “neutral” rating in a report on Monday, June 29th. Truist began coverage on Eli Lilly And Co in a report on Friday. They issued a “buy” rating and a $180.00 price target on the stock. Finally, ValuEngine cut Eli Lilly And Co from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. One analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $170.36.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Marijuana Stocks
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.